Euroopa Liit - eesti - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with abevmy in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics [figo] stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Eesti - eesti - Ravimiamet

norbrook laboratories (ireland) limited - karprofeen - süstelahus - 50mg 1ml 20ml 1tk

Eesti - eesti - Ravimiamet

norbrook laboratories (ireland) limited - tseftiofuur - süstelahuse pulber ja lahusti - 50mg 1ml 1000mg 1tk; 50mg 1ml 4000mg 12tk; 50mg 1ml 4000mg 1tk; 50mg 1ml 1000mg 6tk; 50mg 1ml 4000mg 6tk

Eesti - eesti - Ravimiamet

ipsen consumer healthcare s.a.s. - naatriumsulfaat, veevaba+kaaliumkloriid+naatriumkloriid+makrogool+naatriumvesinikkarbonaat - suukaudse lahuse pulber - 5,7g+0,75g+1,46g+64g+1,68g 4tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivakaftoor - tsüstiline fibroos - muud hingamisteede tooted - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ja 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ja 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Eesti - eesti - Ravimiamet

norbrook laboratories (ireland) limited - amoksitsilliin+klavulaanhape - süstesuspensioon - 140mg+35mg 1ml 50ml 1tk

Eesti - eesti - Ravimiamet

glaxosmithkline (ireland) limited - flutikasoon - inhalatsioonipulber - 50mcg 1annus 60annus 1tk

Eesti - eesti - Ravimiamet

mylan ireland limited - posakonasool - suukaudne suspensioon - 40mg 1ml 105ml 1tk

Eesti - eesti - Ravimiamet

glaxosmithkline (ireland) limited - flutikasoon - inhalatsioonipulber - 100mcg 1annus 60annus 1tk

Eesti - eesti - Ravimiamet

glaxosmithkline (ireland) limited - atsikloviir - infusioonilahuse pulber - 250mg 5tk